Retinal function after intravitreal injection of autologous bone marrow-derived mesenchymal stromal cells in advanced glaucoma.
ERG
Electroretinogram
Glaucoma
Mesenchymal stem cells
Journal
Documenta ophthalmologica. Advances in ophthalmology
ISSN: 1573-2622
Titre abrégé: Doc Ophthalmol
Pays: Netherlands
ID NLM: 0370667
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
24
08
2020
accepted:
05
01
2021
pubmed:
21
1
2021
medline:
21
10
2021
entrez:
20
1
2021
Statut:
ppublish
Résumé
To report electroretinographic (ERG) findings in advanced glaucoma treated with a single intravitreal injection of bone marrow-derived mesenchymal stem cells (MSCs). Intravitreal injection of autologous MSCs (1 × 10 Patients did not show improvement on visual acuity or visual field after treatment. At baseline, ERG responses showed typical findings for advanced glaucoma, with a- and b-wave amplitude and latency within normative range, but reduced photopic negative responses. No noteworthy changes were observed on ERG responses for both cases up to 1 week after treatment, but at day 15, one patient showed retinal detachment with proliferative vitreoretinopathy and was removed from the trial. The other patient kept ERG responses stable throughout study period. Although no ERG response changes were observed after MSCs injection in one case, the complication observed on the second one, along with the lack of visual function improvement, warrants further studies involving modified MSCs to treat ocular disorders, including glaucoma. ClinicalTrials.gov, NCT02330978- missed in pdf.
Identifiants
pubmed: 33469852
doi: 10.1007/s10633-021-09817-z
pii: 10.1007/s10633-021-09817-z
doi:
Banques de données
ClinicalTrials.gov
['NCT02330978']
Types de publication
Case Reports
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
33-38Références
Johnson TV, DeKorver NW, Levasseur VA et al (2014) Identification of retinal ganglion cell neuroprotection conferred by platelet-derived growth factor through analysis of the mesenchymal stem cell secretome. Brain 137(2):503–519
doi: 10.1093/brain/awt292
Park SS, Moisseiev E, Bauer G et al (2017) Advances in bone marrow stem cell therapy for retinal dysfunction. Prog Retin Eye Res 56:148–165
doi: 10.1016/j.preteyeres.2016.10.002
Harrell CR, Fellabaum C, Arsenijevic A, Markovic BS, Djonov V, Volarevic V (2019) Therapeutic potential of mesenchymal stem cells and their secretome in the treatment of glaucoma. Stem Cells Int 2019:7869130
pubmed: 31949441
pmcid: 6948292
Castro A, Du Y (2019) Trabecular meshwork regeneration—a potential treatment for glaucoma. Curr Ophthalmol Rep 7(2):80–88
doi: 10.1007/s40135-019-00203-2
Roubeix C, Godefroy D, Mias C et al (2015) Intraocular pressure reduction and neuroprotection conferred by bone marrow-derived mesenchymal stem cells in an animal model of glaucoma. Stem Cell Res Ther 6:177
doi: 10.1186/s13287-015-0168-0
Mead B, Hill LJ, Blanch RJ et al (2016) Mesenchymal stromal cell-mediated neuroprotection and functional preservation of retinal ganglion cells in a rodent model of glaucoma. Cytotherapy 18(4):487–496
doi: 10.1016/j.jcyt.2015.12.002
Vilela CAP, Souza LEB, Siqueira RC, Calado RT, Covas DT, Paula JS (2018) Ex vivo evaluation of intravitreal mesenchymal stromal cell viability using bioluminescence imaging. Stem Cell Res Ther 9(1):155
doi: 10.1186/s13287-018-0909-y
McCulloch DL, Marmor MF, Brigell MG et al (2015) ISCEV Standard for full-field clinical electroretinography (2015 update). Doc Ophthalmol 130(1):1–12
doi: 10.1007/s10633-014-9473-7
Tzameret A, Sher I, Belkin M et al (2014) Transplantation of human bone marrow mesenchymal stem cells as a thin subretinal layer ameliorates retinal degeneration in a rat model of retinal dystrophy. Exp Eye Res 118:135–144
doi: 10.1016/j.exer.2013.10.023
Mead B, Amaral J, Tomarev S (2018) Mesenchymal stem cell-derived small extracellular vesicles promote neuroprotection in rodent models of glaucoma. Invest Ophthalmol Vis Sci 59(2):702–714
doi: 10.1167/iovs.17-22855
Kuriyan AE, Albini TA, Townsend JH et al (2017) Vision loss after intravitreal injection of autologous “stem cells” for AMD. N Engl J Med 376(11):1047–1053
doi: 10.1056/NEJMoa1609583
Pennock S, Haddock LJ, Eliott D, Mukai S, Kazlauskas A (2014) Is neutralizing vitreal growth factors a viable strategy to prevent proliferative vitreoretinopathy? Prog Retin Eye Res 40:16–34
doi: 10.1016/j.preteyeres.2013.12.006